Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Glioblastoma 7Urinary Bladder Neoplasms 5Lung Neoplasms 5Glioma 5Breast Neoplasms 5Esophageal Neoplasms 4Burkitt Lymphoma 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Carcinoma 3Sarcoma, Ewing 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mouth Neoplasms 2Mesothelioma, Malignant 2Medulloblastoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Gliosarcoma 2Ganglioneuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 55Carboplatin 55Pemetrexed 47Cisplatin 37Paclitaxel 21Nivolumab 20Docetaxel 19durvalumab 18osimertinib 14Gemcitabine 14Cetuximab 14130-nm albumin-bound paclitaxel 14atezolizumab 12Specimen Handling 12Magnetic Resonance Spectroscopy 12amivantamab 10Radiotherapy 8lazertinib 7Taxes 7Radiosurgery 7alectinib 6Ramucirumab 6Observation 6Ipilimumab 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5zimberelimab 4entrectinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Radiation × 30 days × Clear all
NCT03132922 2026-06-04

MAGE-A4ᶜ¹º³²T for Multi-Tumor

USWM, LLC (dba US WorldMeds)

Phase 1 Active not recruiting
71 enrolled 20 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT07619599 2026-06-02

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

City of Hope Medical Center

Phase 1 Not yet recruiting
6 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡